Published in Expert Opin Drug Deliv on February 01, 2010
Integrin targeted delivery of chemotherapeutics. Theranostics (2011) 1.42
aV integrins and TGF-β-induced EMT: a circle of regulation. J Cell Mol Med (2012) 1.07
Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol (2011) 0.90
A cyclic HSV1-TK reporter for real-time PET imaging of apoptosis. Proc Natl Acad Sci U S A (2014) 0.89
Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors. Cell Adh Migr (2011) 0.83
Bone-stromal cells up-regulate tumourigenic markers in a tumour-stromal 3D model of prostate cancer. Mol Cancer (2013) 0.81
Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation. J Oncol (2011) 0.79
Dual-functional c(RGDyK)-decorated Pluronic micelles designed for antiangiogenesis and the treatment of drug-resistant tumor. Int J Nanomedicine (2015) 0.77
In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. Nat Med (2012) 2.13
Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res (2010) 1.26
The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res (2008) 1.24
Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomed Chromatogr (2009) 1.17
Anticonvulsant activity of phenylmethylenehydantoins: a structure-activity relationship study. J Med Chem (2004) 1.14
Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding. Eur J Pharm Sci (2006) 1.10
Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology (Oxford) (2010) 1.10
Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. J Mol Med (Berl) (2011) 1.05
The medicinal use of realgar (As₄S₄) and its recent development as an anticancer agent. J Ethnopharmacol (2011) 1.03
Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells. Pharm Res (2009) 1.03
Shogaols at proapoptotic concentrations induce G(2)/M arrest and aberrant mitotic cell death associated with tubulin aggregation. Apoptosis (2011) 0.95
Development and validation of a gas chromatography/mass spectrometry metabonomic platform for the global profiling of urinary metabolites. Rapid Commun Mass Spectrom (2008) 0.95
Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. Clin Pharmacokinet (2006) 0.93
Ursolic acid inhibits the initiation, progression of prostate cancer and prolongs the survival of TRAMP mice by modulating pro-inflammatory pathways. PLoS One (2012) 0.90
Self-assembled core-shell vascular-targeted nanocapsules for temporal antivasculature and anticancer activities. Small (2010) 0.89
Inclusion of acitretin into cyclodextrins: phase solubility, photostability, and physicochemical characterization. J Pharm Sci (2003) 0.89
A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials (2010) 0.89
Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. Mol Nutr Food Res (2013) 0.88
A simple and sensitive HPLC-UV method for the quantification of piceatannol analog trans-3,5,3',4'-tetramethoxystilbene in rat plasma and its application for a pre-clinical pharmacokinetic study. J Pharm Biomed Anal (2009) 0.88
Fluorescent nanogel of arsenic sulfide nanoclusters. Angew Chem Int Ed Engl (2009) 0.87
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One (2013) 0.86
Determination of Z-3,5,4'-trimethoxystilbene in rat plasma by a simple HPLC method: application in a pre-clinical pharmacokinetic study. J Pharm Biomed Anal (2010) 0.86
A rapid HPLC method for the quantification of 3,5,4'-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. J Pharm Biomed Anal (2008) 0.86
Determination of trans-2,4,3',4',5'-pentamethoxystilbene in rat plasma and its application to a pharmacokinetic study. J Pharm Biomed Anal (2011) 0.85
Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal (2011) 0.85
Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry. J Proteome Res (2013) 0.85
Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. Pharm Res (2010) 0.85
Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity. Antioxid Redox Signal (2013) 0.84
Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. J Pharm Sci (2011) 0.84
Metabonomic profiling of bladder cancer. J Proteome Res (2014) 0.84
A high performance liquid chromatography method for the simultaneous determination of arctiin, chlorogenic acid and glycyrrhizin in a Chinese proprietary medicine. J Pharm Biomed Anal (2005) 0.83
Quantification of oxyresveratrol analog trans-2,4,3',5'-tetramethoxystilbene in rat plasma by a rapid HPLC method: application in a pre-clinical pharmacokinetic study. Biomed Chromatogr (2010) 0.83
Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: application to a pharmacokinetic study. J Pharm Biomed Anal (2012) 0.82
Metabonomic profiling of TASTPM transgenic Alzheimer's disease mouse model. J Proteome Res (2012) 0.82
Quantification of trans-3,4,5,4'-Tetramethoxystilbene in rat plasma by HPLC: application to pharmacokinetic study. J Agric Food Chem (2011) 0.81
Arsenic(II) sulfide quantum dots prepared by a wet process from its bulk. J Am Chem Soc (2008) 0.81
Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As(2)O(3) and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR. Eur J Pharm Sci (2011) 0.81
A novel shogaol analog suppresses cancer cell invasion and inflammation, and displays cytoprotective effects through modulation of NF-κB and Nrf2-Keap1 signaling pathways. Toxicol Appl Pharmacol (2013) 0.80
The histone deacetylase inhibitors MS-275 and SAHA suppress the p38 mitogen-activated protein kinase signaling pathway and chemotaxis in rheumatoid arthritic synovial fibroblastic E11 cells. Molecules (2013) 0.80
Applications of monolithic materials for sample preparation. J Pharm Biomed Anal (2013) 0.80
Evaluation of dried blood spots as sample matrix for gas chromatography/mass spectrometry based metabolomic profiling. Anal Chem (2011) 0.79
Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. J Pharm Biomed Anal (2005) 0.79
Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. Int J Pharm (2010) 0.79
Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation. Int J Oncol (2011) 0.78
A novel dextran-oleate-cRGDfK conjugate for self-assembly of nanodrug. Nanomedicine (2011) 0.78
Identification of metabolites of meisoindigo in rat, pig and human liver microsomes by UFLC-MS/MS. Biochem Pharmacol (2009) 0.78
Determination of tributyrin and its metabolite butyrate in Wistar rat plasma samples by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom (2004) 0.78
Synthesis and in vitro evaluation of 2,4-diamino-1,3,5-triazine derivatives as neuronal voltage-gated sodium channel blockers. Bioorg Med Chem Lett (2009) 0.78
Design of a pectin-based microparticle formulation using zinc ions as the cross-linking agent and glutaraldehyde as the hardening agent for colonic-specific delivery of resveratrol: in vitro and in vivo evaluations. J Drug Target (2010) 0.77
A simple assay for determination of levetiracetam in rat dried blood spots by LC-MS/MS. Bioanalysis (2013) 0.77
Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells. Int J Oncol (2012) 0.77
CdSe/AsS core-shell quantum dots: preparation and two-photon fluorescence. J Am Chem Soc (2009) 0.77
Metabolic footprinting of tumorigenic and nontumorigenic uroepithelial cells using two-dimensional gas chromatography time-of-flight mass spectrometry. Anal Bioanal Chem (2010) 0.77
A retrospective study on the usage of antiepileptic drugs in Asian children from 2000 to 2009 in the largest pediatric hospital in Singapore. Pharmacoepidemiol Drug Saf (2012) 0.77
Formulation and optimization of zinc-pectinate beads for the controlled delivery of resveratrol. AAPS PharmSciTech (2010) 0.76
Isobolographic analysis of the analgesic interactions between ketamine and tramadol. J Pharm Pharmacol (2002) 0.76
Evaluation of tributyrin lipid emulsion with affinity to low-density lipoprotein: pharmacokinetics in adult male Wistar rats and cellular activity on Caco-2 and HepG2 cell lines. J Pharmacol Exp Ther (2005) 0.76
3D-QSAR Study on dihydro-1,3,5-triazines and their spiro derivatives as DHFR inhibitors by comparative molecular field analysis (CoMFA). Bioorg Med Chem Lett (2012) 0.76
Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J (2010) 0.75
Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.75
Quantification of pinosylvin in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pre-clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.75
Polymer-coated microparticles for the sustained release of nitrofurantoin. J Pharm Pharmacol (2002) 0.75
A structure-activity relationship study of 1,2,4-triazolo[1,5-a][1,3,5]triazin-5,7-dione and its 5-thioxo analogues on anti-thymidine phosphorylase and associated anti-angiogenic activities. Eur J Med Chem (2013) 0.75
Antiproliferative activity against MCF-7 breast cancer cells by diamino-triazaspirodiene antifolates. Chem Biol Drug Des (2009) 0.75
Synthesis and in vitro evaluation of 1,2,4-triazolo[1,5-a][1,3,5]triazine derivatives as thymidine phosphorylase inhibitors. Chem Biol Drug Des (2013) 0.75
Identification of circulatory and excretory metabolites of meisoindigo in rat plasma, urine and feces by high-performance liquid chromatography coupled with positive electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom (2010) 0.75
Identification of stereoisomeric metabolites of meisoindigo in rat liver microsomes by achiral and chiral liquid chromatography/tandem mass spectrometry. Drug Metab Dispos (2008) 0.75
Characterization of metabolites of meisoindigo in male and female rat kidney microsomes by high-performance liquid chromatography coupled with positive electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom (2008) 0.75
Extraction of ketamine from urine using a miniature silica monolithic cartridge followed by quantification with liquid chromatography tandem mass spectrometry (LC-MS/MS). J Sep Sci (2011) 0.75
Quantification of arsenic compounds using derivatization, solvent extraction and liquid chromatography electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal (2008) 0.75
Developing a nomogram for dose individualization of phenytoin in Asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug. Ther Drug Monit (2013) 0.75
An automated Pearson's correlation change classification (APC3) approach for GC/MS metabonomic data using total ion chromatograms (TICs). Analyst (2013) 0.75
Biopharmaceutics of beta-cyclodextrin derivative-based formulations of acitretin in Sprague-Dawley rats. J Pharm Sci (2004) 0.75
Speciation of inorganic and methylated arsenic compounds by capillary zone electrophoresis with indirect UV detection. Application to the analysis of alkali extracts of As2S2 (realgar) and As2S3 (orpiment). J Chromatogr A (2004) 0.75
Preparation of tributyrin emulsion and characterization of the binding of the emulsion particles to low-density lipoprotein in vitro. J Pharm Sci (2004) 0.75
Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication. J Clin Pharmacol (2013) 0.75
Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes. Bioorg Med Chem (2009) 0.75
Synthesis and antimicrobial activity of N¹-benzyl or N¹-benzyloxy-1,6-dihydro-1,3,5-triazine-2,4-diamines. Bioorg Med Chem Lett (2011) 0.75
Cytotoxicity, qualitative structure-activity relationship (QSAR), and anti-tumor activity of bismuth dithiocarbamate complexes. J Inorg Biochem (2007) 0.75
Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified beta-cyclodextrins. Int J Pharm (2007) 0.75